We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Parexel International Corp. | NASDAQ:PRXL | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 88.08 | 88.10 | 88.11 | 0 | 01:00:00 |
PAREXEL International Corporation (NASDAQ: PRXL), a leading global biopharmaceutical services organization, today announced that several of its experts will discuss key issues facing the industry at the 53rd Drug Information Association (DIA) Annual meeting, held from June 18 to 22, 2017 in Chicago.
PAREXEL will hold in-booth presentations and technology demonstrations at booth 820 in the exhibit hall. Company experts will share several formal presentations during the program, including:
Sunday, June 18
Monday, June 19
Tuesday, June 20
Wednesday, June 21
To schedule a briefing with a PAREXEL subject matter expert at DIA 2017, email events@parexel.com. For more information about PAREXEL visit booth 820 during the meeting or www.PAREXEL.com. Information about the DIA 2017 can be found at www.diahome.org.
About PAREXEL International
PAREXEL International Corporation is a leading global biopharmaceutical services company, providing a broad range of expertise-based clinical research, consulting, medical communications, and technology solutions and services to the worldwide pharmaceutical, biotechnology, and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, and reimbursement. PAREXEL Informatics provides advanced technology solutions, including medical imaging, to facilitate the integrated clinical development and regulatory information management process. Headquartered near Boston, Massachusetts, PAREXEL has offices in 86 locations in 51 countries around the world, and had approximately 19,370 employees in the third quarter. For more information about PAREXEL International visit www.PAREXEL.com.
PAREXEL and PAREXEL Informatics are trademarks or registered trademarks of PAREXEL International Corporation or its affiliates. All other trademarks are the property of their respective owners.
This release contains “forward-looking” statements regarding future results and events. For this purpose, any statements contained herein that are not statements of historical fact may be deemed forward-looking statements. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects,” “intends,” “appears,” “estimates,” “projects,” “will,” “would,” “could,” “should,” “targets,” and similar expressions are also intended to identify forward-looking statements. The forward-looking statements in this release involve a number of risks and uncertainties. Such factors and others are discussed in the section entitled “Risk Factors” of the Company’s most recent Annual Report on Form 10-K and subsequent quarterly reports on Form 10-Q filed with the Securities and Exchange Commission, which “Risk Factors” discussion is incorporated by reference in this press release. The Company specifically disclaims any obligation to update these forward-looking statements in the future. These forward-looking statements should not be relied upon as representing the Company’s estimates or views as of any date subsequent to the date of this press release.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170612005930/en/
Media:Dana RobieTel.: +1 781-434-4772Email: Dana.Robie@PAREXEL.comorKathryn McMahon, PAN CommunicationsTel.: +1 617-502-4300Email: PAREXEL@pancomm.comorInvestors:Ronald AldridgeTel.: +1 781-434-4753Email: Ron.Aldridge@PAREXEL.com
1 Year Parexel Chart |
1 Month Parexel Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions